Calcium CaV1 Channel Subtype mRNA Expression in Parkinson’s Disease Examined by In Situ Hybridization

Journal of Molecular Neuroscience

Volumn 55, Issue 3, 2015, Pages 715-724

  Hurley, Michael J ^a   Gentleman, Steve M ^a   Dexter, David T ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Brain; Calcium channel; Dihydropyridines; In situ hybridization; Parkinson s disease

Indexed keywords

ALPHA SYNUCLEIN; CALCIUM CHANNEL CAV1.2; CALCIUM CHANNEL CAV1.3; MESSENGER RNA; SULFUR 35; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; ALPHA1D (CAV1.3) L-TYPE CALCIUM CHANNEL, HUMAN; CALCIUM CHANNEL L TYPE;

AGED; ARTICLE; BRAIN CORTEX; CALCIUM HOMEOSTASIS; CELL LOSS; CINGULATE GYRUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LOCUS CERULEUS; MALE; OLIGONUCLEOTIDE PROBE; PARKINSON DISEASE; PRIMARY MOTOR CORTEX; SUBSTANTIA NIGRA; VERY ELDERLY; ANTIBODY SPECIFICITY; CASE CONTROL STUDY; GENETICS; MESENCEPHALON; METABOLISM; MOTOR CORTEX;

ANIMALIA;

AGED; AGED, 80 AND OVER; CALCIUM CHANNELS, L-TYPE; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MESENCEPHALON; MOTOR CORTEX; ORGAN SPECIFICITY; PARKINSON DISEASE; RNA, MESSENGER;

EID: 84922241473     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-014-0410-8     Document Type: Article

References (45)

1. Alafuzoff I, Ince PG, Arzberger T et al (2009) Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 117:635–652
2. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215:403–410
3. Becker C, Jick SS, Meier CR (2008) Use of antihypertensives and the risk of Parkinson disease. Neurology 70:1438–1444
4. 2+ channels. J Biol Chem 286:42736–42748
5. Braak H, Del TK, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
6. Chan CS, Guzman JN, Ilijic E et al (2007) ‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease. Nature 447:1081–1086
7. Chan CS, Glajch KE, Gertler TS et al (2011) HCN channelopathy in external globus pallidus neurons in models of Parkinson’s disease. Nat Neurosci 14:85–92
8. Durrenberger PF, Grunblatt E, Fernando FS et al (2012) Inflammatory pathways in Parkinson’s disease; a BNE microarray study. Parkinson’s Dis 2012:214714
9. 2+ channel gene expression. J Neurosci 19:3345–3352
10. Fujimura K, Matsuda Y (1989) Autogenous oscillatory potentials in neurons of the guinea pig substantia nigra pars compacta in vitro. Neurosci Lett 104:53–57
11. Gegg ME, Burke D, Heales SJR et al (2012) Glucocerebrosidase deficiency in substantia nigra of Parkinson’s disease brains. Ann Neurol 72:455–463
12. Goldberg JA, Guzman JN, Estep CM et al (2012) Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson’s disease. Nat Neurosci 15:1414–1421
13. Guzman JN, Sanchez-Padilla J, Wokosin D et al (2010) Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468:696–702
14. Hashioka S, Klegeris A, McGeer PL (2012) Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. Neuropharmacology 63:685–691
15. Huang H, Yu D, Soong TW (2013) C-terminal alternative splicing of CaV1.3 channels distinctively modulates their dihydropyridine sensitivity. Mol Pharmacol 84:643–653
16. Hurley MJ, Dexter DT (2012) Voltage-gated calcium channels and Parkinson’s disease. Pharmacol Ther 133:324–333
17. Hurley MJ, Jenner P (2006) What has been learnt from study of dopamine receptors in Parkinson’s disease? Pharmacol Ther 111:715–728
18. 3 receptors in rat brain. Psychopharmacol (Berl) 128:362–370
19. V1 channels and calcium-binding proteins. Brain 136:2077–2097
20. Ilijic E, Guzman JN, Surmeier DJ (2011) The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson’s disease. Neurobiol Dis 43:364–371
21. V1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson’s disease. Nat Commun 3:1146
22. Khaliq ZM, Bean BP (2010) Pacemaking in dopaminergic ventral tegmental area neurons: depolarizing drive from background and voltage-dependent sodium conductances. J Neurosci 30:7401–7413
23. Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH (1996) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 741:185–196
24. Lees AJ, Hardy J, Revesz T (2009) Parkinson’s disease. Lancet 373:2055–2066
25. Marras C, Gruneir A, Rochon P et al (2012) Dihydropyridine calcium channel blockers and the progression of parkinsonism. Ann Neurol 71:362–369
26. Mercuri NB, Bonci A, Calabresi P, Stratta F, Stefani A, Bernardi G (1994) Effects of dihydropyridine calcium antagonists on rat midbrain dopaminergic neurones. Br J Pharmacol 113:831–838
27. Möller T (2002) Calcium signaling in microglia cells. Glia 40:184–194
28. 2+ conductances in guinea-pig substantia nigra pars compacta neurones. J Physiol 466:727–747
29. Nunez DJ, Davenport AP, Emson PC, Brown MJ (1989) A quantitative ‘in-situ’ hybridization method using computer-assisted image analysis. Validation and measurement of atrial-natriuretic-factor mRNA in the rat heart. Biochem J 263:121–127
30. Nuzzo R (2014) Statistical errors. Nature 506:150–152
31. Parkinson Study Group (2013) Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson’s disease (STEADY-PD). Mov Disord 28:1823–1831
32. Pasternak B, Svanstrom H, Nielsen NM, Fugger L, Melbye M, Hviid A (2012) Use of calcium channel blockers and Parkinson’s disease. Am J Epidemiol 175:627–635
33. Przedborski S, Vila M, Jackson-Lewis V (2003) Neurodegeneration: what is it and where are we? J Clin Invest 111:3–10
34. Puopolo M, Raviola E, Bean BP (2007) Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J Neurosci 27:645–656
35. Rees K, Stowe R, Patel S (2011) Antihypertensive drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies and clinical trials. Cochrane Database Syst Rev 11:CD008535. doi:10.1002/14651858.CD008535.pub2
36. Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S (2010) L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 67:600–606
37. Sautter J, Kupsch A, Earl CD, Oertel WH (1997) Degeneration of pre-labelled nigral neurons induced by intrastriatal 6-hydroxydopamine in the rat: behavioural and biochemical changes and pretreatment with the calcium-entry blocker nimodipine. Exp Brain Res 117:111–119
38. Schlick B, Flucher BE, Obermair GJ (2010) Voltage-activated calcium channel expression profiles in mouse brain and cultured hippocampal neurons. Neuroscience 167:786–798
39. Sinnegger-Brauns MJ, Huber IG, Koschak A et al (2009) Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol 75:407–414
40. Surmeier DJ (2007) Calcium, ageing, and neuronal vulnerability in Parkinson’s disease. Lancet Neurol 6:933–938
41. Surmeier DJ, Guzman JN, Sanchez J, Schumacker PT (2012) Physiological phenotype and vulnerability in Parkinson’s disease. Cold Spring Harb Perspect Med 2:a009290
42. V1.3 channels. J Biol Chem 286:42725–42735
43. Ton TG, Heckbert SR, Longstreth WT Jr et al (2007) Calcium channel blockers and beta-blockers in relation to Parkinson’s disease. Parkinsonism Relat Disord 13:165–169
44. Vogt IR, Lees AJ, Evert BO, Klockgether T, Bonin M, Wullner U (2006) Transcriptional changes in multiple system atrophy and Parkinson’s disease putamen. Exp Neurol 199:465–478
45. Wilson CJ, Callaway JC (2000) Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J Neurophysiol 83:3084–3100